Core Viewpoint - Tianyu Bio announced the termination of the "Tianchang City Longgang Red Cultural Tourism Scenic Area Project" to improve the efficiency of raised fund usage, reallocating the remaining funds to supplement working capital [2] Group 1: Project Details - The adjusted investment amount for the project is 275.71 million yuan [2] - As of November 30, 2025, the company has invested a total of 216.48 million yuan, achieving a progress rate of 78.52% [2] - The remaining unused raised funds amount to 59.68 million yuan, which includes cash management income and net bank interest received after deducting fees [2] Group 2: Corporate Governance - The decision to terminate the project was approved by the company's fifth board of directors in its fifth meeting [2] - The matter will be submitted for review at the company's first extraordinary shareholders' meeting in 2026 [2]

Group 1 - The company raised a total of RMB 402.27 million through a private placement of 48.35 million shares at a price of RMB 8.32 per share, with a net amount of RMB 393.87 million after deducting issuance costs [1][3] - As of June 30, 2025, the balance of the raised funds in the special account was RMB 187,615.74, with an additional RMB 61.69 million remaining unutilized, accounting for 15.33% of the total raised funds [2][3] - The company plans to use the remaining funds according to the construction progress of the Tianchang Longgang Red Culture Tourism Scenic Area project, which is expected to be completed by 2025 [2][3] Group 2 - The company has approved the temporary use of idle raised funds for working capital, with amounts of RMB 130 million, RMB 220 million, and RMB 160 million used in different periods, all of which have been returned to the special account [1][2] - The internal rate of return for the Tianchang Longgang Red Culture Tourism Scenic Area project has been adjusted from 25% to 17% due to project delays, impacting the expected cumulative gross profit [2][3] - The company has confirmed that the actual use of raised funds aligns with the disclosures made in annual reports and other information disclosure documents, with no discrepancies found [2][3]